TABLE 2

Effects of IL-1β treatment on expression of transporters

		-Fold Repression (mRNA levels)^a
Gene	Exposure Time to IL-1β	Human Hepatocytes (n = 6)	HepaRG Cells (n = 4)
	h
OATP-B	8	4.1 ± 1.0^b (2.3-5.7)^c *	3.0 ± 0.6^d *
	24	6.0 ± 2.0 (3.7-10.9)*	25.4 ± 3.1*
OATP-C	8	2.5 ± 0.4 (2.1-3.5)*	2.8 ± 0.8*
	24	8.8 ± 1.7 (5.2-12.1)*	25.5 ± 8.1*
OATP8	8	3.4 ± 0.9 (2.0-5.8)*	1.1 ± 0.1
	24	8.1 ± 3.0 (3.8-13.5)*	1.9 ± 0.5*
BSEP	8	3.1 ± 0.7 (1.4-4.3)*	2.4 ± 0.5*
	24	7.1 ± 2.9 (2.4-15.9)*	10.9 ± 5.1*
BCRP	8	2.2 ± 0.4 (1.6-20.8)*	2.5 ± 0.4*
	24	3.7 ± 1.5 (1.8-8.1)*	4.1 ± 0.9*
MRP2	8	1.9 ± 0.3 (1.4-2.4)*	1.6 ± 0.3*
	24	2.3 ± 0.5 (1.7-3.9)*	3.2 ± 0.7*
MRP3	8	1.7 ± 0.3 (1.2-2.0)*	1.6 ± 0.1*
	24	1.9 ± 0.3 (1.4-2.7)*	2.5 ± 0.3*
MRP4	8	0.8 ± 0.1 (0.7-1.0)^e *	0.5 ± 0.1^f *
	24	1.8 ± 0.4 (1.0-2.3)*	0.6 ± 0.1^g *

↵* , p < 0.05 when compared with mRNA levels in untreated cells.
↵ a Defined as the ratio of mRNA levels in untreated cells versus those found in IL-1β-exposed cells.
↵ b Expressed as mean ± S.E.M. of values from six independent hepatocyte populations.
↵ c Numbers in parentheses indicate the repression range for the six hepatocyte populations analyzed in the study.
↵ d Expressed as mean ± S.E.M. of values from four independent experiments.
↵ e,f,g Correspond to 1.3-, 2.0-, and 1.7-fold factor of induction, respectively.